Our Stock of the Week is Apellis Pharmaceuticals (APLS). APLS is a commercial-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
In February 2023, the FDA approved Syfovre as the first-ever treatment for geographic atrophy (GA) caused by age-related macular degeneration (AMD).
On January 8, 2024, APLS issued upside guidance for Q4, seeing revenues of $138 mln vs. $123.08 mln FactSet Consensus. APLS also expects approximately $366 mln for the full year 2023 for SYFOVRE for geographic atrophy (GA) secondary to age-related macular degeneration.
There have been several upgrades based on this guidance. The launch of Syfovre is going well, and it should have a good earnings report when it reports around February 26.
Technically, the stock spiked up on the positive guidance and has been fading back to support. We are looking for entry at support to take advantage of a possible runup as the market anticipates strong earnings at the end of the month.
As always, we would not chase the stock on Monday but would aggressively trade the volatility.
This post is for educational purposes only! This is not advice or a recommendation. We do not give investment advice. Do not act on this post. Do not buy, sell, or trade the stocks mentioned herein. We WILL actively trade this stock differently than discussed herein. We will sell into strength and buy or sell anytime for any reason. We will actively trade into any unusual activity. At the time of this post, principals, employees, and affiliates of Shark Investing, Inc. and/or principals, clients, employees, and affiliates of Hammerhead Financial Strategies, LLC, directly or indirectly, controlled investment and/or trading accounts containing positions in APLS. To accommodate the objectives of these investing and/or trading accounts, the trading in these shares will be contrary to and/or inconsistent with the information contained in this posting.
